Warning Letter — Genzyme Ireland Limited
The FDA issued a Warning Letter to Genzyme Ireland Limited following an inspection by the Center for Biologics Evaluation and Research (CBER).
This letter affects Genzyme Ireland Limited and its biologics manufacturing, quality assurance, and regulatory compliance teams.
The issuance of a Warning Letter by CBER indicates that the facility's manufacturing or quality control processes failed to meet regulatory standards during the inspection. This action suggests that existing compliance measures may be insufficient, potentially necessitating significant remediation efforts to resolve the cited deficiencies and maintain site standing with the agency.
Sites should conduct a thorough gap analysis of current manufacturing and quality systems against established biologics regulations. QA and Manufacturing leads should prioritize ensuring all corrective actions address root causes identified during the CBER inspection to prevent recurrence of the cited issues.
FDA Warning Letter issued to: Genzyme Ireland Limited. 06/22/2026 — Center for Biologics Evaluation and Research (CBER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genzyme-ireland-limited-728681-06222026
Open in openFDA / FDA.gov